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The prevalence of HIV-associated neurocognitive disorders necessitates community-based screening. In recent years, progress 
has been made in developing more localised comparative data for use in such screening on the African continent. These studies 
used measurements that are considered fair, easily accessible, and quick to administer. However, the variance in available 
international data limits their usefulness and poses a risk to the appropriate streaming of individuals. Here, examples are 
presented of variance in both cross-national and local demographic screening and neuropsychological test scores, with the aim 
of cautioning practitioners against undue reliance on general African data for classification of individuals. Recommendations 
are provided for the development of appropriate norms, specific to local communities.
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South Africa (SA) is home to the world’s largest population of 
people living with HIV and AIDS (PLWHA), with an estimated 
HIV prevalence of 16.9% among SA adults (aged 15 - 49 
years) in 2008.[1] Recent figures suggest that 17 - 25% of HIV 
patients in SA display cognitive impairment,[2,3] the diagnosis 
of which is largely dependent on the deviation of test scores 
from standardised norms. HIV-associated neurocognitive 
disorders (HANDs) are diagnosed using the Frascati model,[4] 
which requires neuropsychological scores to be compared with 
normative data using standard deviation (SD) as an indicator 
of impairment.
The classification of neurocognitive impairment requires 
clinical attention as it influences decisions on treatment 
initiation, the management of daily living, and so forth. Owing 
to the large number of people affected and the prevalence of 
impairment, large-scale screening is imperative and streams 
identified individuals towards further investigation. This 
process requires measurements that are fair, easily accessible 
and quick to administer. In this regard, the International 
HIV Dementia Scale (IHDS) and Grooved Pegboard (GP) 
are arguably the most widely used instruments for HAND 
screening in limited-resource communities,[5] and these have 
been shown to differentiate between the HIV statuses of 
asymptomatic patients in sub-Saharan Africa.[6,7] 
The problem of variance
Data from the IHDs and GP tests, and from the rest of the 
World Health Organization (WHO) HIV battery, have been 
reported from various sites in sub-Saharan Africa. This is 
positive progress, as the developing world norms differ from 
those of industrialised countries,[8] and practitioners may 
need to use comparative data from Africa when no local data 
are available. However, despite these positive developments, 
the issue of data variability across countries has not been 
resolved.[9] An example of the range of scores for HIV-negative 
respondents on the IHDS and GP is provided in Table 1. Table 
2 provides an example of the range of scores for HIV-negative 
respondents for some of the tests used across countries in 
Eastern and Southern Africa.
In terms of screening, there are some difficulties when 
comparing SA scores with other African data for local use. 
For example, the IHDS total score range equals an SD of ±1 
across some countries (Table 1). Given that the recommended 
cut-off for streaming towards further investigation for possible 
neurocognitive impairment is ≤10,[7] this could have significant 
implications for individuals across different countries. 
Additionally, the range of the IHDS memory recall subtest 
differs noticeably between different demographic subgroups 
within one location.[12] The GP-non-dominant hand test 
(GP-NDH) also differs significantly across countries. This is 
an important HAND screening mechanism, and the variance 
in published data creates difficulties for interpretation and 
further streaming. 
Similar problems are faced in terms of diagnosis. For 
example, the range of the Trail Making Test (TMT) scores 
differs by more than ±1 SD between different demographic 
subgroups within one location.[12] The Digit Symbol Modalities 










Table 2. Scores for TGT, DSMT, TMT and DS conducted among HIV-negative respondents in East and Southern 
Africa
Country Test N Mean SD
Zambia[10] TGT 57 12.3  
Uganda[7] DSMT 100 31.10 ±11.30
TGT 100 6.95 ±0.82
DSF 100 5.30 ±0.90
DSB 100 3.50 ±0.90
South Africa[6] TMT-A 24 43.74 ±12.40
DSMT 24 50.54 ±11.10
South Africa[12] TMT-A (female; aged 18 - 29 years) 40.73 ±17.40
TMT-A (male; aged 18 - 29 years) 35.89 ±8.94
All aged 18 - 29 years (N=68) TMT-A (female; aged 30 - 50 years) 48.54 ±18.70
All aged 30 - 50 years (N=42) TMT-A (male; aged 30 - 50 years) 50.00 ±13.60
TMT-B (female; aged 18 - 29 years) 72.57 ±26.00
TMT-B (male; aged 18 - 29 years) 87.78 ±26.50
TMT-B (female; aged 30 - 50 years) 89.26 ±28.40
TMT-B (male; aged 30 - 50 years) 114.25 ±43.10
DSF (female; aged 18 - 29 years) 6.50 ±1.38
DSF (male; aged 18 - 29 years) 6.33 ±1.12
DSF (female; aged 30 - 50 years) 6.14 ±1.40
DSF (male; aged 30 - 50 years) 6.00 ±1.07
DSB (female; aged 18 - 29 years) 3.63 ±0.97
DSB (male; aged 18 - 29 years) 4.56 ±0.73
DSB (female; aged 30 - 50 years) 3.29 ±0.83
DSB (male; aged 30 - 50 years) 3.88 ±0.99
TGT = Timed Gait Test; DSMT = Digit Symbol Modalities Test; TMT-A = Trail Making Test A; TMT-B = Trail Making Test B; DS = Digit Span; DSF = Digit Span Forward; DSB = Digit Span Backward.
Table 1. Scores for IHDS and GP-NDH tests conducted among HIV-negative respondents in East and 
Southern Africa
Country Test N Mean SD
Zambia[10] IHDS total 57 10.10  
IHDS memory recall 57 3.40  
GP-NDH 57 97.50
Uganda[11] IHDS 25 11.10 ±0.80
Uganda[7] IHDS total 100 11.00 ±1.00
IHDS memory recall 100 3.60 ±0.60
GP-NDH 100 102.70 ±25.20
South Africa[6] GP-NDH 24 80.83 ±9.20
South Africa[12] IHDS memory recall (female; aged 18 - 29 years) 3.77 ±0.47
IHDS memory recall (male; aged 18 - 29 years) 3.39 ±0.55
IHDS memory recall (female; aged 30 - 50 years) 3.66 ±0.48
IHDS memory recall (male; aged 30 - 50 years) 3.19 ±0.96
SD = standard deviation; IHDS = International HIV Dementia Scale; GP-NDH = Grooved Pegboard-non-dominant hand test. 





Digit Span (DS) Forward and Backward scores also display ranges 
equalling an SD of ±1 between some countries (most notably Uganda 
and South Africa) and even within countries, based on demographics. 
The Timed Gait Test (TGT) score range equals an SD of ±6 between 
samples in Zambia and Uganda.[7,10] This is despite indications in the 
reported studies suggesting that the samples had broadly similar socio-
economic and educational backgrounds.
While it is tempting to believe that the variance is simply due to 
inter-country differences, there may be a number of reasons why it may 
not reflect true cross-national or cross-cultural differences. Firstly, it 
is not always clear whether psychologists, primary healthcare nursing 
personnel or highly qualified researchers performed the assessments. 
Some tests (e.g. IHDS) were developed to be administered by primary 
healthcare workers, while others were (at least historically) firmly 
placed in the neuropsychological domain (e.g. GP, TMT). Secondly, 
there is a lack of demographic reporting. The effects of gender, age, 
education, and so forth, are well documented,[5,12] but not equally well-
reported across studies, consequently limiting comparison. Thirdly, the 
samples are often small (N<50 in the case of the SA samples), which 
may not reflect the larger population.[13] Fourthly, viral subtypes may 
further limit comparison between HIV-1 clades.[8,14] 
Using general scores from African samples may, therefore, not be 
appropriate when placing people in categories of impairment using 
SD from normative scores. The intention of this article is to caution 
researchers and practitioners against an over-reliance on cross-national 
‘African’ data to create ‘local’ norms, which may result in inappropriate 
diagnostic classification. 
Looking forward
Given the incidence of HANDs in SA, there is a critical requirement for 
valid norms to guide screening and eventual diagnosis. The problematic 
nature of comparing across national (and presumably cultural) 
borders emphasises the need for assessment that is fair to patients. 
This includes: firstly, the development of localised norms – in terms of 
specific communities – that, at the very least, are reported in terms of 
age, gender and education (socio-economic status, ethnicity and testing 
language may also be valuable); and secondly, the use of larger samples 
that have reasonable validity.[13] There are further concerns about the 
responsibility of test administration, in light of the possible effects of the 
tester on outcome variance.[15] Here, a balance must be struck between 
making assessment accessible to the community and maintaining the 
integrity of the neuropsychological nature of the tests. A tiered approach 
– i.e. screening with the IHDS by primary healthcare workers, referral 
to community-based psychologists for an expanded battery (e.g. WHO 
HIV battery), and further referral to specialist clinics for extended 
neuropsychological assessment – is recommended.
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